Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Adverse events were frequent, and most were gastrointestinal-related, including nausea, vomiting, diarrhea, constipation.

(Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) For those who are overweight or obese, medications known as glucagon-like peptide-1 agonists, or GLP-1s, have become very ...

Between Novo Nordisk's (NVO) slightly disappointing results for its latest GLP-1 candidate, CagriSema, and questions that remain about Amgen's (AMGN) highly anticipated once-monthly injectable ...

GLP-1 agonists like Ozempic effectively help manage obesity, but quitting the medication can lead to a resurgence in weight and related health issues. Gradual cessation is advised to avoid sudden ...

Nestlé’s efforts to attract users of GLP-1 drugs in the US now include the launch of protein shots. The company is rolling out Boost Pre-meal, a liquid shot the Swiss giant said will “support ...

The weight-loss properties of GLP-1 drugs, including Ozempic and Wegovy, have dominated headlines. But could they also cut alcohol consumption? And what would this mean for beverage manufacturers? The ...

GLP-1 weight-loss drugs have dominated healthcare headlines in 2024, marked by expanded employer coverage, dynamic pricing changes, and pharmaceutical giants like Novo Nordisk (NVO) and Eli Lilly ...

Nestlé’s efforts to attract users of GLP-1 drugs in the US now include the launch of protein shots. The company is rolling out Boost Pre-meal, a liquid shot the Swiss giant said will “support people ...

Hims & Hers stock took a hit today after the FDA ruled no shortage of tirzepatide, impacting their compounded GLP-1 drug offerings. Despite the setback, Hims & Hers' CEO will likely remain defiant ...